Summary
Forget Zepbound: 3 Newer Drugs That Could Power Eli Lilly's Next Leg Higher
Eli Lilly could continue to dominate the weight-loss market thanks to medicines like Foundayo and retatrutide. The company's latest approval strengthens its diabetes portfolio.
Here's Why Eli Lilly (LLY) Fell More Than Broader Market
Eli Lilly (LLY) reached $1 at the closing of the latest trading day, reflecting a -1.04% change compared to its last close.
Prediction: Eli Lilly Could Have More Room to Grow Than Its Valuation Suggests
Eli Lilly trades at a premium multiple, yet its revenue growth dwarfs every major pharma peer by a wide margin. Whether that gap justifies buying shares near all-time highs depends on one critical assumption about Lilly's pipeline.
Eli Lilly and Company (LLYd) FAQ
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Eli Lilly and Company ever had a stock split?
Eli Lilly and Company Profile
| Pharmaceuticals Industry | Healthcare Sector | David A. Ricks CEO | CBOE Exchange | US5324571083 ISIN |
| US Country | 50,000 Employees | 14 Aug 2026 Last Dividend | 16 Oct 1997 Last Split | 13 Jan 1978 IPO Date |
Overview
Eli Lilly and Company is a global leader in the discovery, development, and marketing of human pharmaceuticals. With a history dating back to 1876, the company has established itself as a key player in the pharmaceutical industry, offering a wide range of products aimed at treating a variety of conditions. Headquartered in Indianapolis, Indiana, Eli Lilly and Company has forged multiple collaborations with other pharmaceutical giants such as Incyte Corporation, Boehringer Ingelheim Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd, Genentech, Inc., Biologics, Inc., AbCellera Biologics Inc., and Chugai Pharmaceutical Co., Ltd., enhancing its product offerings and research capabilities across different therapeutic areas.
Products and Services
- Diabetes Care
Includes a comprehensive portfolio of insulin and other diabetes treatments: Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500. Additionally, the company offers Jardiance, Mounjaro, and Trulicity for managing type 2 diabetes.
- Oncology
Provides a range of products for cancer treatment, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio, focusing on different types of cancer and treatment approaches.
- Immunology
Olumiant is offered for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19. Taltz is available for treating plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis.
- Digestive Diseases
Omvoh is targeted at ulcerative colitis, reflecting the company's commitment to addressing gastrointestinal disorders.
- Neurological Disorders
Includes Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain. Emgality is provided for migraine prevention and treatment of episodic cluster headache.
- Other Therapeutic Areas
The company also offers Cialis for erectile dysfunction and benign prostatic hyperplasia; Forteo for osteoporosis treatment; Zepbound for obesity management; and Ebglyss for severe atopic dermatitis, showcasing Eli Lilly's diverse portfolio catering to various health conditions.
Contact Information
